$PDSB
PDS Biotechnology Corp

2020 Q4 Form 10-Q Financial Statement

#000114036120025429 Filed on November 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.530M $1.850M $3.000M
YoY Change 273.17% -38.33% -15.49%
% of Gross Profit
Research & Development $2.480M $2.061M $1.834M
YoY Change 83.7% 12.34% 845.22%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $30.00K
YoY Change 0.0% -100.0% -25.0%
% of Gross Profit
Operating Expenses $4.030M $3.907M $5.847M
YoY Change 128.98% -33.18% 723.26%
Operating Profit -$3.907M -$5.847M
YoY Change -33.18% 723.26%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.030M -$3.910M -$5.750M
YoY Change -11.62% -32.0% 34.66%
Income Tax
% Of Pretax Income
Net Earnings -$4.030M -$3.906M -$5.752M
YoY Change -3.59% -32.09% 708.71%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$180.7K -$206.2K -$1.095M
COMMON SHARES
Basic Shares Outstanding 22.26M 15.36M 5.247M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.80M $33.50M $17.40M
YoY Change 136.07% 92.53% -52.72%
Cash & Equivalents $28.84M $33.47M $17.41M
Short-Term Investments
Other Short-Term Assets $1.500M $400.0K $700.0K
YoY Change -34.78% -42.86% 250.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $30.34M $33.84M $18.13M
YoY Change 109.65% 86.63% -51.12%
LONG-TERM ASSETS
Property, Plant & Equipment $5.443K $9.345K $26.93K
YoY Change -74.14% -65.3% -94.61%
Goodwill
YoY Change
Intangibles $2.974M $2.974M $1.223M
YoY Change 0.0% 143.17%
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $553.1K $602.9K $1.250M
YoY Change 2527.66% -51.76% 108.32%
TOTAL ASSETS
Total Short-Term Assets $30.34M $33.84M $18.13M
Total Long-Term Assets $553.1K $602.9K $1.250M
Total Assets $30.89M $34.45M $19.38M
YoY Change 113.17% 77.7% -48.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.415M $1.560M $1.489M
YoY Change 18.16% 4.74% 148.16%
Accrued Expenses $1.735M $1.223M $1.297M
YoY Change 58.1% -5.69% 44.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.270M $2.899M $3.644M
YoY Change 17.07% -20.45% -45.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $500.0K $500.0K
YoY Change
Total Long-Term Liabilities $500.0K $500.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.270M $2.899M $3.644M
Total Long-Term Liabilities $500.0K $500.0K $0.00
Total Liabilities $3.761M $3.400M $3.800M
YoY Change 34.62% -10.53% -43.28%
SHAREHOLDERS EQUITY
Retained Earnings -$43.79M -$39.76M -$23.83M
YoY Change 51.31% 66.81%
Common Stock $7.346K $7.346K $1.742K
YoY Change 321.7% 321.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.13M $31.02M $15.58M
YoY Change
Total Liabilities & Shareholders Equity $30.89M $34.45M $19.38M
YoY Change 113.17% 77.7% -48.58%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$4.030M -$3.906M -$5.752M
YoY Change -3.59% -32.09% 708.71%
Depreciation, Depletion And Amortization $10.00K $0.00 $30.00K
YoY Change 0.0% -100.0% -25.0%
Cash From Operating Activities -$4.630M -$1.250M -$4.320M
YoY Change -16.12% -71.06% -52.84%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $19.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 17.79M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -4.630M -1.250M -4.320M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 0.000 17.79M 0.000
Net Change In Cash -4.630M 16.54M -4.320M
YoY Change -11.81% -482.87% -52.84%
FREE CASH FLOW
Cash From Operating Activities -$4.630M -$1.250M -$4.320M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
11200
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1559591
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1197720
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1097640
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1222773
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
256062
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
101470
CY2020Q3 us-gaap Accrued Rent Current
AccruedRentCurrent
0
CY2019Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
221934
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
70775892
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40633670
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
300898
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2893658
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
120207
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
129792
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300898
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
120206
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2893658
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
129792
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1837271
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1668660
CY2019Q4 us-gaap Assets
Assets
14491252
CY2020Q3 us-gaap Assets
Assets
34445255
CY2019Q4 us-gaap Assets Current
AssetsCurrent
14470201
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2020Q3 us-gaap Assets Current
AssetsCurrent
33842330
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
12161739
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
29106512
CY2019Q3 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
0
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
11939331
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
0
CY2020Q3 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
0
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12161739
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33468935
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
17302913
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
21307196
CY2020Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
33468935
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12161739
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103695
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17406608
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33468935
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00033
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00033
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5281237
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22261619
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5281237
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22261619
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
7346
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1742
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10820574
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5751610
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3905822
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2820763
CY2019Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
3573760
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
32953
CY2020Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
19967
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
29704
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
19967
CY2019Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
29704
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
29705
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
19967
us-gaap Depreciation
Depreciation
11706
us-gaap Depreciation
Depreciation
93814
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1424897
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
CY2019Q3 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-944445
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-944445
CY2020Q3 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-310951
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
CY2019Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
300000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9358429
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1846214
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5428098
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3068581
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q3 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-1211939
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-498185
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1521516
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
361871
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
125133
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-900622
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1908520
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1935067
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2974000
us-gaap Interest Expense
InterestExpense
0
CY2020Q3 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
606
CY2019Q3 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
606
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
95787
us-gaap Investment Income Interest
InvestmentIncomeInterest
54242
us-gaap Investment Income Interest
InvestmentIncomeInterest
294694
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1207
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
603924
CY2020Q3 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P40M
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0915
CY2019Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
38365
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
58665
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
140678
CY2020Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
35700
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34445255
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14491252
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2898604
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2793545
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="color: #000000; font-weight: bold;">Note 1 &#8211; Nature of Operations</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; color: #000000;">PDS Biotechnology Corporation, a Delaware corporation (the &#8220;Company,&#8221; &#8220;PDS,&#8221; or the &#8220;combined company&#8221;), PDS is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies and infectious disease vaccines designed to overcome the well-established limitations of current immunotherapy technologies. PDS owns Versamune<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, a proprietary T-cell activating platform designed to train the immune system to better attack and destroy disease. When paired with an antigen,&#160; which is a disease-related protein that is recognizable by the immune system, Versamune<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> has been shown to induce, <font style="font-style: italic;">in vivo,</font> large quantities of high-quality, highly potent polyfunctional CD8+ killer T-cells, a specific sub-type of CD8+ killer T-cell that is more effective at killing infected or target cells. Our immuno-oncology products can potentially be used as a component of combination products with other leading technologies to provide effective treatments across a range of cancer types, including Human Papillomavirus (HPV)-based cancers, melanoma, colorectal, lung, breast and prostate cancers or as monotherapies in early-stage disease. PDS is working to expand its infectious disease pandemic development program, which includes novel vaccines for COVID-19 and universal influenza, in addition to its previously announced tuberculosis development collaboration with Farmacore Biotechnology.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; color: #000000;">From the Company&#8217;s inception, it has devoted substantially all of its efforts to drug development, business planning, engaging regulatory, manufacturing and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; color: #000000;">On March 15, 2019, the Company, then operating as Edge Therapeutics, Inc. (&#8220;Edge&#8221;), completed its reverse merger with privately held PDS Biotechnology Corporation (&#8220;Private PDS&#8221;), pursuant to and in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated as of November 23, 2018, as amended on January 24, 2019, by and among the Company, Echos Merger Sub, a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), and Private PDS, whereby Private PDS merged with and into Merger Sub, with Private PDS surviving as the Company&#8217;s wholly-owned subsidiary (the &#8220;Merger&#8221;).<font style="font-style: italic;">&#160;</font>In connection with and immediately following completion of the Merger, the Company effected a 1-for-20 reverse stock split (the &#8220;Reverse Stock Split&#8221;) and changed its corporate name from Edge Therapeutics, Inc. to PDS Biotechnology Corporation, and Private PDS changed its name to PDS Operating Corporation.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; color: #000000;">For accounting purposes, the Merger was treated as a &#8220;reverse acquisition&#8221; under generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and Private PDS is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Private PDS became the Company&#8217;s historical financial statements, and the historical financial statements of Private PDS are included in the comparative prior periods. See &#8220;Note 4 &#8211; Reverse Merger&#8221; for more information on the Merger. As part of the Merger, the Company acquired all of Edge&#8217;s assets relating to current and future research and development.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt; color: #000000;">In December 2019, a novel (new) coronavirus known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People&#8217;s Republic of China, causing outbreaks of the coronavirus disease, known as COVID-19, that has now spread globally. On January 30, 2020 the World Health Organization (WHO) declared COVID-19 a public health emergency. The Secretary of Health and Human Services declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to the COVID-19 outbreak. On March 11, 2020, the WHO declared COVID-19 a pandemic. The full impact of the COVID-19 pandemic is unknown and rapidly evolving. The COVID-19 pandemic has and could continue to negatively affect the Company&#8217;s liquidity and operations.&#160; To date, two of the three recently initiated PDS0101 clinical trials have been delayed, specifically as a result of the adverse impact the COVID-19 pandemic has had on clinical trial operations for cancer indications in the United States. Even though both of these studies have since been initiated despite the pandemic challenges, the evolving COVID-19 pandemic has also impacted the pace of enrollment in clinical trials and we may be affected by similar delays as patients may avoid or may not be able to travel to healthcare facilities and physicians&#8217; offices unless due to a health emergency and clinical trial staff can no longer get to the clinic.</div></div>
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8519765
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12553599
us-gaap Net Income Loss
NetIncomeLoss
-2820763
us-gaap Net Income Loss
NetIncomeLoss
-10820574
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3905822
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-5751610
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29106512
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
750000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29826961
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
0
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
15793638
us-gaap Operating Lease Payments
OperatingLeasePayments
62597
us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0915
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1200000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
700000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
637932
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
521692
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
116240
us-gaap Operating Expenses
OperatingExpenses
15054182
us-gaap Operating Expenses
OperatingExpenses
10874816
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
3907029
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
5847397
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
593580
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
700000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1200000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
106949
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P35M
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5847397
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3907029
us-gaap Operating Income Loss
OperatingIncomeLoss
-15054182
us-gaap Operating Income Loss
OperatingIncomeLoss
-10874816
us-gaap Payments For Restructuring
PaymentsForRestructuring
498185
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13000000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9345
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21051
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2308462
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
373395
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
70459
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29756502
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
750000
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19000000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
593580
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1834371
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4751308
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2060815
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5446718
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
498185
CY2020Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2019Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
498185
CY2020Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
0
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39758279
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28937705
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y0M25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M20D
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y0M29D
CY2020Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
17100000
CY2020Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
11900000
us-gaap Share Based Compensation
ShareBasedCompensation
2893658
us-gaap Share Based Compensation
ShareBasedCompensation
300898
CY2019Q3 us-gaap Share Price
SharePrice
5.76
CY2020Q1 us-gaap Share Price
SharePrice
1.30
CY2020Q3 us-gaap Share Price
SharePrice
2.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9700
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9222
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8988
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.10
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.30
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.00
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0149
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0038
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0233
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
32953
CY2019Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
1599178
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
29704
CY2020Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
0
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
19967
CY2019Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
4461
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
10000000
CY2020Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6900000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
15793638
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17786500
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29756502
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
750000
CY2019Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
31024959
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11697707
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-1700517
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
17014489
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
20605615
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
15582597
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"><tr><td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">(B)</td><td style="width: auto; vertical-align: top;"><div style="color: rgb(0, 0, 0); font-weight: bold;">Use of estimates:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt; color: #000000;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates.</div></div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4729153
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18961619
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14892764
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5246829
CY2020Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1105888
CY2019Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
603229
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
PDS Biotechnology Corp
dei Entity Central Index Key
EntityCentralIndexKey
0001472091
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22261619
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Small Business
EntitySmallBusiness
true
CY2020Q3 pdsb Number Of Planned Clinical Trials
NumberOfPlannedClinicalTrials
3
CY2020Q3 pdsb Number Of Planned Clinical Trials Delayed
NumberOfPlannedClinicalTrialsDelayed
2
CY2019Q1 pdsb In The Money Shares Paid Out In Cash
InTheMoneySharesPaidOutInCash
753
CY2019Q1 pdsb Fractional Shares Paid Out In Cash
FractionalSharesPaidOutInCash
235
CY2019Q4 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
16415
CY2020Q3 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
15415
CY2020Q3 pdsb Number Of Equity Based Compensation Plans
NumberOfEquityBasedCompensationPlans
4
CY2019Q3 pdsb Operating Lease Remaining Lease Payments
OperatingLeaseRemainingLeasePayments
665802
CY2019Q3 pdsb Operating Lease Number Of Installments For Remaining Lease Payment
OperatingLeaseNumberOfInstallmentsForRemainingLeasePayment
3
CY2019Q3 pdsb Operating Lease Percentage Of Remaining Payments Required To Be Paid To Terminate Lease
OperatingLeasePercentageOfRemainingPaymentsRequiredToBePaidToTerminateLease
0.5
CY2020Q3 pdsb Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
pdsb Stock Issued During Period Value Equity Transaction
StockIssuedDuringPeriodValueEquityTransaction
603924
CY2019Q3 pdsb Stock Issued During Period Value Equity Transaction
StockIssuedDuringPeriodValueEquityTransaction
603924
CY2019Q3 pdsb Stock Issued During Period Shares Equity Transaction
StockIssuedDuringPeriodSharesEquityTransaction
100654
pdsb Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
70459
pdsb Stock Issued During Period Value Antidilution Protection
StockIssuedDuringPeriodValueAntidilutionProtection
0
CY2020Q3 pdsb Cumulative Proceeds From Issuance Of Common Stock
CumulativeProceedsFromIssuanceOfCommonStock
29800000
pdsb Common Stock Purchase Agreement Term
CommonStockPurchaseAgreementTerm
P30M
CY2020Q3 pdsb Common Stock Purchase Agreement Cumulative Shares Sold
CommonStockPurchaseAgreementCumulativeSharesSold
0
CY2019Q3 pdsb Common Stock Purchase Agreement Shares That Can Be Sold Percentage
CommonStockPurchaseAgreementSharesThatCanBeSoldPercentage
0.1999
CY2020Q3 pdsb Shelf Registration Statement Registered Securities
ShelfRegistrationStatementRegisteredSecurities
100000000
CY2020Q3 pdsb Shelf Registration Statement Available For Future Sale
ShelfRegistrationStatementAvailableForFutureSale
81000000
CY2019Q1 pdsb Percentage Of Shares Owned In Combined Common Stock Prior To Merger
PercentageOfSharesOwnedInCombinedCommonStockPriorToMerger
0.7
CY2019Q1 pdsb Conversion Of Stock Shares Converted
ConversionOfStockSharesConverted
0.3262

Files In Submission

Name View Source Status
0001140361-20-025429-index-headers.html Edgar Link pending
0001140361-20-025429-index.html Edgar Link pending
0001140361-20-025429.txt Edgar Link pending
0001140361-20-025429-xbrl.zip Edgar Link pending
brhc10016888_10q.htm Edgar Link pending
brhc10016888_ex31-1.htm Edgar Link pending
brhc10016888_ex31-2.htm Edgar Link pending
brhc10016888_ex32-1.htm Edgar Link pending
brhc10016888_ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image00002.jpg Edgar Link pending
pdsb-20200930.xml Edgar Link completed
pdsb-20200930.xsd Edgar Link pending
pdsb-20200930_cal.xml Edgar Link unprocessable
pdsb-20200930_def.xml Edgar Link unprocessable
pdsb-20200930_lab.xml Edgar Link unprocessable
pdsb-20200930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending